- Home
- EOSE vs RNA Comparison
EOSE vs RNA Comparison
Compare EOSE & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EOSE | RNA |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | EOSE | RNA |
|---|---|---|
| Price | $13.72 | $71.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 20 |
| Target Price | $12.25 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 22.2M | 2.4M |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $63,458,000.00 | $20,868,000.00 |
| Revenue This Year | $881.87 | $64.11 |
| Revenue Next Year | $230.67 | $37.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 324.10 | 106.27 |
| 52 Week Low | $3.07 | $21.51 |
| 52 Week High | $19.86 | $71.88 |
Technical Indicators
Market Signals| Indicator | EOSE | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 46.80 | 74.47 |
| Support Level | $13.83 | $71.18 |
| Resistance Level | $16.49 | $71.79 |
| Average True Range (ATR) | 1.37 | 0.34 |
| MACD | 0.05 | -0.58 |
| Stochastic Oscillator | 33.62 | 83.93 |
Price Performance
Historical ComparisonAbout EOSE Eos Energy Enterprises Inc.
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial & industrial (C&I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector. It's flagship product Eos Znyth is a stationary battery energy storage system.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.